Search Results

There are 7546 results for: content related to: Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactone

  1. Spironolactone for hypertension

    Intervention Review

    The Cochrane Library

    Josh Batterink, Sarah N Stabler, Aaron M Tejani and Curt T Fowkes

    Published Online : 4 AUG 2010, DOI: 10.1002/14651858.CD008169.pub2

  2. You have free access to this content
    Interventions for hirsutism (excluding laser and photoepilation therapy alone)

    Intervention Review

    The Cochrane Library

    Esther J van Zuuren, Zbys Fedorowicz, Ben Carter and Nikolaos Pandis

    Published Online : 28 APR 2015, DOI: 10.1002/14651858.CD010334.pub2

  3. You have full text access to this OnlineOpen article
    Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice

    EMBO Molecular Medicine

    Michael C Wehr, Wilko Hinrichs, Magdalena M Brzózka, Tilmann Unterbarnscheidt, Alexander Herholt, Jan P Wintgens, Sergi Papiol, Maria Clara Soto-Bernardini, Mykola Kravchenko, Mingyue Zhang, Klaus-Armin Nave, Sven P Wichert, Peter Falkai, Weiqi Zhang, Markus H Schwab and Moritz J Rossner

    Version of Record online : 25 JUL 2017, DOI: 10.15252/emmm.201707691

  4. You have free access to this content
    Aldosterone antagonists for preventing the progression of chronic kidney disease

    Intervention Review

    The Cochrane Library

    Davide Bolignano, Suetonia C Palmer, Sankar D Navaneethan and Giovanni FM Strippoli

    Published Online : 29 APR 2014, DOI: 10.1002/14651858.CD007004.pub3

  5. The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

    European Journal of Pain

    Volume 18, Issue 3, March 2014, Pages: 386–395, T.O. Lilius, V. Jokinen, M.S. Neuvonen, A.J. Väänänen, M. Niemi, P.V. Rauhala and E.A. Kalso

    Version of Record online : 30 JUL 2013, DOI: 10.1002/j.1532-2149.2013.00371.x

  6. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne

    Intervention Review

    The Cochrane Library

    Julie Brown, Cindy Farquhar, Olivia Lee, Robyn Toomath and Ruth G Jepson

    Published Online : 15 APR 2009, DOI: 10.1002/14651858.CD000194.pub2

  7. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease

    Intervention Review

    The Cochrane Library

    Audra Stewart, Luc P Brion and Iris Ambrosio-Perez

    Published Online : 7 SEP 2011, DOI: 10.1002/14651858.CD001817.pub2

  8. Comparison of electrospun and extruded soluplus®-based solid dosage forms of improved dissolution

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 1, January 2012, Pages: 322–332, Zsombor K. Nagy, Attila Balogh, Balázs Vajna, Attila Farkas, Gergő Patyi, Áron Kramarics and György Marosi

    Version of Record online : 23 AUG 2011, DOI: 10.1002/jps.22731

  9. You have full text access to this OnlineOpen article
    Spironolactone use and risk of incident cancers: a retrospective, matched cohort study

    British Journal of Clinical Pharmacology

    Volume 83, Issue 3, March 2017, Pages: 653–663, Isla S. Mackenzie, Steven V. Morant, Li Wei, Alastair M. Thompson and Thomas M. MacDonald

    Version of Record online : 12 NOV 2016, DOI: 10.1111/bcp.13152

  10. A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 3, June 2010, Pages: 260–267, J. GUYONNET, J. ELLIOTT and V. KALTSATOS

    Version of Record online : 11 SEP 2009, DOI: 10.1111/j.1365-2885.2009.01130.x

  11. You have free access to this content
    Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure

    European Journal of Heart Failure

    Volume 16, Issue 2, February 2014, Pages: 143–150, Javaid Iqbal, Yasir Parviz, Bertram Pitt, John Newell-Price, Abdallah Al-Mohammad and Faiez Zannad

    Version of Record online : 14 DEC 2013, DOI: 10.1111/ejhf.31

  12. HYPERKALEMIC CHANGES DURING SPIRONOLACTONE THERAPY FOR CIRRHOSIS AND ASCITES, WITH SPECIAL REFERENCE TO HYPERKALEMIC INTERMITTENT PARALYSIS

    Journal of the American Geriatrics Society

    Volume 16, Issue 8, August 1968, Pages: 874–886, János P. Radó, Judit Marosi, László Szende and József Takó

    Version of Record online : 27 APR 2015, DOI: 10.1111/j.1532-5415.1968.tb02682.x

  13. Spironolactone effect on potassium supplementation in paediatric cardiac intensive care patients

    Journal of Clinical Pharmacy and Therapeutics

    Volume 42, Issue 4, August 2017, Pages: 433–437, B. S. Moffett, T. E. Haworth, Y. Wang, N. Afonso and P. A. Checchia

    Version of Record online : 5 APR 2017, DOI: 10.1111/jcpt.12525

  14. Spironolactone Blocks Glucocorticoid-Mediated Hearing Preservation in Autoimmune Mice

    The Laryngoscope

    Volume 112, Issue 2, February 2002, Pages: 298–303, Neil D. Gross, J. Beth Kempton and Dennis R. Trune

    Version of Record online : 2 JAN 2009, DOI: 10.1097/00005537-200202000-00018

  15. You have free access to this content
    Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine

    Basic & Clinical Pharmacology & Toxicology

    Volume 120, Issue 1, January 2017, Pages: 38–45, Viljami Jokinen, Tuomas Lilius, Jouko Laitila, Mikko Niemi, Oleg Kambur, Eija Kalso and Pekka Rauhala

    Version of Record online : 21 JUL 2016, DOI: 10.1111/bcpt.12634

  16. You have free access to this content
    Treatment Considerations With Aldosterone Receptor Antagonists

    The Journal of Clinical Hypertension

    Volume 13, Issue 1, January 2011, Pages: 65–69, Domenic A. Sica and John M. Flack

    Version of Record online : 4 OCT 2010, DOI: 10.1111/j.1751-7176.2010.00377.x

  17. Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS810L)

    Clinical and Experimental Pharmacology and Physiology

    Volume 43, Issue 10, October 2016, Pages: 995–1003, Seol-Hee Kang, Hae-Ahm Lee, Eunjo Lee, Mina Kim and Inkyeom Kim

    Version of Record online : 1 SEP 2016, DOI: 10.1111/1440-1681.12614

  18. You have free access to this content
    Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

    European Journal of Heart Failure

    Volume 19, Issue 8, August 2017, Pages: 974–986, João Pedro Ferreira, Robert J. Mentz, Anne Pizard, Bertram Pitt and Faiez Zannad

    Version of Record online : 12 APR 2017, DOI: 10.1002/ejhf.814

  19. Spironolactone as a single agent for long-term therapy of hirsute patients

    Clinical Endocrinology

    Volume 52, Issue 5, May 2000, Pages: 587–594, Poli Mara Spritzer, Karen O. Lisboa, Simone Mattiello and Francisco Lhullier

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2265.2000.00982.x

  20. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS

    Journal of Mass Spectrometry

    Volume 41, Issue 4, April 2006, Pages: 477–486, Haijuan Dong, Fengguo Xu, Zunjian Zhang, Yuan Tian and Yun Chen

    Version of Record online : 15 MAR 2006, DOI: 10.1002/jms.1006